menu
    • menu

    Company profile for RS Oncology

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    RS Oncology is a pioneering biotechnology company at the forefront of scientific discoveries and international collaborations, dedicated to enhancing the lives of patients grappling with rare and aggressive cancers. The company is actively engaged in the development of innovative therapies designed to modulate mitochondrial pathways associated with diseases characterized by oxidative stress, with an initial emphasis on cancer....
    RS Oncology is a pioneering biotechnology company at the forefront of scientific discoveries and international collaborations, dedicated to enhancing the lives of patients grappling with rare and aggressive cancers. The company is actively engaged in the development of innovative therapies designed to modulate mitochondrial pathways associated with diseases characterized by oxidative stress, with an initial emphasis on cancer. Through its cutting-edge approach, RS Oncology aims to bring about significant advancements in the treatment of these challenging medical conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RS OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.rsoncology.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rs-oncology/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/RSOncologyLLC?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Trinity Biotech Enters Oncology with EpiCapture Acquisition
    Trinity Biotech Enters Oncology with EpiCapture Acquisition

    25 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/25/2969458/8624/en/Trinity-Biotech-Enters-Oncology-Space-with-Acquisition-of-Prostate-Cancer-Focused-EpiCapture.html

    GLOBENEWSWIRE
    25 Oct 2024
    Share Share
    RS Oncology's RSO-021 Shows Positive Mesothelioma Phase 1 Data
    RS Oncology's RSO-021 Shows Positive Mesothelioma Phase 1 Data

    03 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240603559175/en

    BUSINESSWIRE
    03 Jun 2024
    Share Share
    RS Oncology Novel Cancer Therapy Oral Presentation At ASCO
    RS Oncology Novel Cancer Therapy Oral Presentation At ASCO

    01 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240501350515/en

    BUSINESSWIRE
    01 May 2024
    Share Share
    RS Oncology Announces First Patient Dosed in Phase 2 Study Investigating RSO-021
    RS Oncology Announces First Patient Dosed in Phase 2 Study Investigating RSO-021

    01 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240201668709/en

    BUSINESSWIRE
    01 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search